Financial Performance - The company's revenue for Q1 2024 was ¥97,906,175.23, representing a 7.57% increase compared to ¥91,015,564.31 in the same period last year[5] - Net profit attributable to shareholders was ¥9,583,923.21, a slight increase of 0.47% from ¥9,539,039.25 year-on-year[5] - Basic earnings per share for Q1 2024 were ¥0.0856, unchanged from the adjusted figure of ¥0.0852 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥97,906,175.23, an increase of 7.8% compared to ¥91,015,564.31 in Q1 2023[25] - Net profit for Q1 2024 was ¥9,583,923.21, slightly up from ¥9,539,039.25 in Q1 2023, indicating a marginal increase of 0.5%[25] - The total comprehensive income for the first quarter of 2024 was CNY 9,583,923.21, compared to CNY 9,539,039.25 in the previous period, reflecting a slight increase[26] Cash Flow - The net cash flow from operating activities improved significantly to ¥20,854,970.76, a 287.42% increase from a negative cash flow of ¥11,127,387.13 in the previous year[5] - Cash inflow from operating activities totaled CNY 114,185,746.23, while cash outflow was CNY 93,330,775.47, resulting in a net cash inflow[29] - Cash flow from investment activities generated a net inflow of CNY 553,248.35, compared to a net outflow of CNY 47,058,615.93 in the previous year[29] - Total cash inflow from financing activities was CNY 1,402,082.95, while cash outflow was CNY 5,318,651.24, resulting in a net cash outflow of CNY 3,916,568.29[29] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥830,090,032.63, a decrease of 1.04% from ¥838,823,832.71 at the end of the previous year[5] - Total current liabilities decreased to ¥24,973,746.29 from ¥37,914,519.96, a significant drop of 34.1%[24] - The company's cash and cash equivalents increased to ¥377,541,958.90 from ¥359,853,060.69 at the beginning of the quarter, representing a growth of 4.7%[23] - Accounts receivable decreased to ¥69,823,311.54 from ¥77,834,775.75, a decline of 10.3%[23] - Inventory levels decreased to ¥69,068,331.15 from ¥77,712,454.91, a reduction of 11.1%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,782[15] - The largest shareholder, Hong Wei, holds 38.14% of the shares, amounting to 42,713,286 shares[15] - The company plans to repurchase shares with a total amount not exceeding RMB 120 million, with a maximum repurchase price of RMB 23.00 per share[20] - As of March 31, 2024, the company has repurchased a total of 355,965 shares, accounting for 0.3178% of the current share capital[20] - The highest transaction price for repurchased shares was RMB 15.90 per share, while the lowest was RMB 14.34 per share[20] - The total number of restricted shares at the end of the period is 58,776,465 shares, with 1,031,580 shares released during the period[19] - The company has a total of 59,808,045 restricted shares at the beginning of the period[19] Expenses and Investments - The company reported a research and development expense of ¥4,123,227.36, which is an increase from ¥3,646,778.89 in the previous year, reflecting a growth of 13.1%[25] - The company reported a significant decrease in financial expenses, with a net loss of ¥1,306,295.12, a 256.22% increase compared to the previous year's loss of ¥366,714.15[11] - The fair value change income was reported at ¥535,835.98, a substantial increase of 1495.41% from a loss of ¥38,400.00 in the previous year[11] - The company experienced a decrease in cash received from tax refunds, totaling ¥294,294.67, down 85.73% from ¥2,062,148.50 in the previous year[13] - Cash paid for purchasing goods and services decreased by 48.04% to ¥56,003,583.38 from ¥107,781,820.59 in the previous year[13] Other Information - The company did not report any significant changes in user data or new product developments during the quarter[30] - The first quarter report was not audited, indicating that the figures may be subject to change upon final audit[30]
美农生物(301156) - 2024 Q1 - 季度财报